Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have received an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.67.

Several equities analysts have recently commented on the company. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Thursday, March 20th. D. Boral Capital reissued a “buy” rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. William Blair initiated coverage on shares of Immunic in a report on Tuesday, March 25th. They issued an “outperform” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, February 21st.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IMUX. State Street Corp grew its position in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. 683 Capital Management LLC lifted its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares during the period. Bridgeway Capital Management LLC boosted its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares in the last quarter. Focus Partners Wealth increased its position in Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares during the period. Finally, Virtu Financial LLC bought a new position in Immunic in the 3rd quarter worth $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Down 3.2 %

NASDAQ:IMUX opened at $1.20 on Friday. The stock has a market cap of $108.09 million, a P/E ratio of -0.98 and a beta of 1.89. The business’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.21. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.